{
    "clinical_study": {
        "@rank": "46725", 
        "arm_group": [
            {
                "arm_group_label": "tetracycline/furazolidone", 
                "arm_group_type": "Experimental", 
                "description": "one of the four empirical rescue therapies"
            }, 
            {
                "arm_group_label": "amoxicillin/tetracycline", 
                "arm_group_type": "Experimental", 
                "description": "one of the four empirical rescue therapies"
            }, 
            {
                "arm_group_label": "amoxicillin/furazolidone", 
                "arm_group_type": "Experimental", 
                "description": "one of the four empirical rescue therapies"
            }, 
            {
                "arm_group_label": "tetracycline /metronidazole", 
                "arm_group_type": "Active Comparator", 
                "description": "Classical rescue therapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The increase of antibiotic resistance to H. pylori causes failure of treatment.\n      Furazolidone, amoxicillin and tetracycline are good candidates for rescue therapy since\n      resistance to these three antimicrobials was rare. It is necessary to assess the efficacy\n      and safety of these four bismuth-containing quadruple regimens with above antibiotics as\n      empirical rescue therapies for H. pylori eradication."
        }, 
        "brief_title": "Empirical Rescue Therapies of Helicobacter Pylori Infection", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Functional Dyspepsia", 
            "Scarred Peptic Ulcer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyspepsia", 
                "Peptic Ulcer", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  H. pylori -positive patients with functional dyspepsia and scarred peptic ulcers who\n             had previously failed one or more eradication regimens containing clarithromycin,\n             metronidazole and/or amoxicillin.\n\n        Exclusion Criteria:\n\n          -  less than 18 years old, never receiving eradication treatment before, with previous\n             gastric surgery, pregnancy, lactation, major systemic diseases, administration of\n             antibiotics, bismuth, antisecretory drugs in the preceding 8 weeks"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "424", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668927", 
            "org_study_id": "rjkls_2012009"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "tetracycline/furazolidone", 
                    "amoxicillin/tetracycline", 
                    "amoxicillin/furazolidone", 
                    "tetracycline /metronidazole"
                ], 
                "intervention_name": "Proton Pump Inhibitor", 
                "intervention_type": "Drug", 
                "other_name": "Lansoprazole"
            }, 
            {
                "arm_group_label": [
                    "tetracycline/furazolidone", 
                    "amoxicillin/tetracycline", 
                    "amoxicillin/furazolidone", 
                    "tetracycline /metronidazole"
                ], 
                "intervention_name": "Bismuth", 
                "intervention_type": "Drug", 
                "other_name": "Bismuth potassium citrate"
            }, 
            {
                "arm_group_label": "tetracycline /metronidazole", 
                "intervention_name": "Metronidazole", 
                "intervention_type": "Drug", 
                "other_name": "metronidazole"
            }, 
            {
                "arm_group_label": [
                    "tetracycline/furazolidone", 
                    "amoxicillin/tetracycline", 
                    "tetracycline /metronidazole"
                ], 
                "intervention_name": "Tetracycline", 
                "intervention_type": "Drug", 
                "other_name": "tetracycline"
            }, 
            {
                "arm_group_label": [
                    "tetracycline/furazolidone", 
                    "amoxicillin/furazolidone"
                ], 
                "intervention_name": "Furazolidone", 
                "intervention_type": "Drug", 
                "other_name": "Furazolidone"
            }, 
            {
                "arm_group_label": [
                    "amoxicillin/tetracycline", 
                    "amoxicillin/furazolidone"
                ], 
                "intervention_name": "Amoxicillin", 
                "intervention_type": "Drug", 
                "other_name": "Amoxicillin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetracycline", 
                "Amoxicillin", 
                "Furazolidone", 
                "Metronidazole", 
                "Bismuth", 
                "Potassium Citrate", 
                "Proton Pump Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200127"
                }, 
                "name": "Renji Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Helicobacter Pylori Treatment", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "eradication rate of H. pylori", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668927"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Dr. HONG LU", 
            "investigator_title": "professor of GI Division, Renji Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}